

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: DALE B. SCHENKApplication No./Patent No.: 10/823,463Filed/Issue Date: April 12, 2004Titled: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASEJanssen Alzheimer Immunotherapy, a Corporation

(Name of Assignees)

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that they are:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %); or
3. ☐ Janssen Alzheimer Immunotherapy and Wyeth LLC are each an assignee of an undivided right, title, and interest in the patent application identified above. There are no other assignees.

the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: DALE B. SCHENK To: ELAN PHARMACEUTICALS, INC.

The document was recorded in the United States Patent and Trademark Office at

Reel 023105, Frame 0188, or for which a copy thereof is attached.

2. From: ELAN PHARMACEUTICALS, INC. To: NEURALAB LIMITED

The document was recorded in the United States Patent and Trademark Office at

Reel 023105, Frame 0311, or for which a copy thereof is attached.

3. From: NEURALAB LIMITED To: ELAN PHARMA INTERNATIONAL LIMITED

The document was recorded in the United States Patent and Trademark Office at

Reel 023105, Frame 0528, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet (s).

- ☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

/Rosemarie L. Celli/

Signature

August 10, 2010

Date

Rosemarie L. Celli, Registration No. 42,397

Printed or Typed Name

Attorney of Record

Title

Supplemental Sheet to Statement Under 3.73(b)  
Attorney Docket No.: 057437-391782  
Application No.: 10/823,463  
Filing Date: April 12, 2004

Additional documents in the chain of title:

4. From: ELAN PHARMA INTERNATIONAL LIMITED To: CRIMAGUA LIMITED  
The document was recorded in the United States Patent and Trademark Office at  
Reel: 023341 Frame: 0795; or for which a copy thereof is attached.
5. From: CRIMAGUA LIMITED To: JANSSEN ALZHEIMER IMMUNOTHERAPY  
The document was recorded in the United States Patent and Trademark Office at  
Reel: 023341 Frame: 0805; or for which a copy thereof is attached.